Premium
To PARP or not to PARP?—Toward sensitizing acute myeloid leukemia stem cells to immunotherapy
Author(s) -
Heyman Benjamin,
Jamieson Catriona
Publication year - 2019
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.15252/embj.2019103479
Subject(s) - stem cell , myeloid leukemia , cancer , medicine , cancer research , immunology , oncology , biology , genetics
A new study reveals that leukemia stem cells ( LSC s) in acute myeloid leukemia downregulate natural killer cell‐activating receptor ligands to evade immune surveillance via the transcriptional co‐factor PARP 1. The inhibition of PARP 1 sensitizes LSC s to immunotherapy, highlighting its potential as a therapeutic target.